{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:49:02Z","timestamp":1772772542770,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jfma.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T20:25:35Z","timestamp":1557951935000},"page":"230-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P2","title":["Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy"],"prefix":"10.1016","volume":"119","author":[{"given":"Yung-Tsu","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-3279","authenticated-orcid":false,"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.04.020_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib2","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2019.04.020_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jfma.2019.04.020_bib4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.04.020_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisolone versus prednisolone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2019.04.020_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(00)90213-5","article-title":"Patterns of remission in pemphigus vulgaris","volume":"42","author":"Herbst","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","volume":"94","author":"Cho","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jfma.2019.04.020_bib11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib12","author":"National Cancer Institute"},{"key":"10.1016\/j.jfma.2019.04.020_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/1346-8138.13757","article-title":"Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up","volume":"44","author":"Kim","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamadermatol.2017.5176","article-title":"Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfma.2019.04.020_bib17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2019.04.020_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2710.2006.00707.x","article-title":"Molecular analysis of thiopurine S-methyltransferase alleles in Taiwan aborigines and Taiwanese","volume":"31","author":"Lu","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jfma.2019.04.020_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dsi.2013.07.001","article-title":"Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients","volume":"32","author":"Wang","year":"2013","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jfma.2019.04.020_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Chams-Davatchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461830860X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461830860X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:40:23Z","timestamp":1760539223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966461830860X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S092966461830860X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.04.020","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}